ADD THIS DRUG TO MY LIST

Select the drug indication to add to your list

TRULICITY
Diabetes
Compare To Related Drugs
View/Edit/Compare Drugs In My List

Only 4 drugs may be compared at once

Drug Name:

TRULICITY Rx

Generic Name and Formulations:
Dulaglutide 0.75mg/0.5mL, 1.5mg/0.5mL; per pen or prefilled syringe; soln for SC inj.

Company:
Lilly, Eli and Company

Therapeutic Use:

Indications for TRULICITY:

Adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes.

Limitations Of use:

Not recommended as first-line treatment for patients inadequately controlled on diet and exercise. Not studied in patients with history of pancreatitis. Not for treating type 1 diabetes or diabetic ketoacidosis. Not a substitute for insulin. Not recommended in patients with pre-existing severe GI disease.

Adult:

Give by SC inj in the abdomen, thigh, or upper arm any time of the day, with or without food. ≥18yrs: initially 0.75mg once weekly; may increase to max 1.5mg once weekly if inadequate response. Renal impairment: caution with initiating or escalating doses.

Children:

<18yrs: not recommended.

Contraindications:

History (personal or family) of medullary thyroid carcinoma. Multiple endocrine neoplasia syndrome type 2.

Warnings/Precautions:

Risk of thyroid C-cell tumors; inform patients of risk and symptoms. Monitor for pancreatitis; discontinue if suspected; do not restart if confirmed. History of pancreatitis; consider other antidiabetic therapies. Discontinue if hypersensitivity reactions occur; treat promptly and monitor until resolve. History of angioedema or anaphylaxis. Monitor renal function in renally-impaired patients reporting severe GI reactions. Hepatic impairment. Pregnancy. Nursing mothers.

Interactions:

Increased risk of hypoglycemia with concomitant sulfonylureas or insulin; consider reducing their doses. May affect absorption of other oral drugs (delayed gastric emptying); monitor drugs with narrow therapeutic index.

Pharmacological Class:

Glucagon-like peptide-1 (GLP-1) receptor agonist.

Adverse Reactions:

Nausea, diarrhea, vomiting, abdominal pain, decreased appetite, dyspepsia; acute pancreatitis.

REMS:

YES

Generic Availability:

NO

How Supplied:

Single-dose pen—4; Single-dose prefilled syringe—4

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs